IDEXX Laboratories, Inc. (IDXX) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 22 analysts33.0% Below Target
IDXX trades 33.0% below Wall Street's consensus target of $747.50.
Current Price$562.09
Average Target$747.50
Target
Current
Low$640.00
Median$775.00
High$800.00
Analyst Target Range
Forward P/E38.3x
(Growth Premium)
PEG Ratio2.69
(Pricey)
Implied Growth+8.0%
(Low)
Analyst Spread21.4%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes IDXX achieves its forward estimates and maintains a stable P/E multiple of 38.3x. This scenario reflects the blended consensus of 22 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
IDXX Price Target Analysis
Updated June 21, 2026As of June 21, 2026, IDEXX Laboratories, Inc. (IDXX) has a Wall Street consensus price target of $747.50, based on estimates from 22 covering analysts. With the stock currently trading at $562.09, this represents a potential upside of +33.0%. The company has a market capitalization of $44.64B.
Analyst price targets range from a low of $640.00 to a high of $800.00, representing a 21% spread in expectations. The median target of $775.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 13 analysts rating the stock as a Buy or Strong Buy,8 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, IDXX trades at a trailing P/E of 43.0x and forward P/E of 38.3x. The forward PEG ratio of 2.69 reflects a premium valuation. Analysts expect EPS to grow +8.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $711.07, with bear and bull scenarios of $447.97 and $936.91 respectively. Model confidence stands at 68/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+32.3%
Industry Consensus
Avg Forward P/E
19.8x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ZTSZoetis Inc. | $33.0B | $78.71 | $120.80 | +53.5% | Hold | 11.4x | 30 |
 HSICHenry Schein, Inc. | $9.2B | $79.92 | $87.43 | +9.4% | Buy | 14.9x | 33 |
 ELANElanco Animal Health Incorporated | $12.1B | $24.22 | $28.40 | +17.3% | Buy | 22.9x | 20 |
 ANIPANI Pharmaceuticals, Inc. | $1.8B | $79.49 | $124.00 | +56.0% | Buy | 8.5x | 10 |
 NEOGNeogen Corporation | $2.0B | $9.31 | $11.00 | +18.2% | Hold | 25.2x | 11 |
 CHWYChewy, Inc. | $7.5B | $18.21 | $31.54 | +73.2% | Buy | 23.1x | 38 |
 DHRDanaher Corporation | $125.4B | $177.17 | $230.89 | +30.3% | Buy | 21.0x | 43 |
 BIOBio-Rad Laboratories, Inc. | $7.6B | $282.44 | $321.67 | +13.9% | Buy | 31.2x | 14 |
 TMOThermo Fisher Scientific Inc. | $172.7B | $464.61 | $599.70 | +29.1% | Buy | 18.7x | 42 |
 AAgilent Technologies, Inc. | $35.9B | $127.06 | $154.75 | +21.8% | Buy | 21.0x | 41 |
IDXX — Frequently Asked Questions
Quick answers to the most common questions about buying IDXX stock.
What is the IDXX stock price target for 2026?
The consensus Wall Street price target for IDXX is $747.5, representing 33.0% upside from the current price of $562.09. With 22 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is IDXX a buy, sell, or hold?
IDXX has a consensus rating of "Buy" based on 22 Wall Street analysts. The rating breakdown is predominantly bullish, with 13 Buy/Strong Buy ratings. The consensus 12-month price target of $747.5 implies 33.0% upside from current levels.
Is IDXX stock overvalued or undervalued?
At a forward P/E of 38.3467x, IDXX trades at a premium valuation. The consensus price target of $747.5 (33.0% upside) suggests analysts still see growth justifying the multiple.
How high can IDXX stock go?
The most bullish Wall Street analyst has a price target of $800 for IDXX, while the most conservative target is $640. The consensus of $747.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $937 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover IDXX stock?
IDXX is well covered by analysts, with 22 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 13 have Buy ratings, 8 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the IDXX stock forecast?
The 12-month IDXX stock forecast based on 22 Wall Street analysts shows a consensus price target of $747.5, with estimates ranging from $640 (bear case) to $800 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $711, with bear/bull scenarios of $448/$937.
What is IDXX's fair value based on fundamentals?
Our quantitative valuation model calculates IDXX's fair value at $711 (base case), with a bear case of $448 and bull case of $937. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 68/100.
What is IDXX's forward P/E ratio?
IDXX trades at a forward P/E ratio of 38.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 43.0x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy IDXX stock?
Wall Street analysts are very optimistic on IDXX, with a "Buy" consensus rating and $747.5 price target (33.0% upside). 13 of 22 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do IDXX price targets vary so much?
IDXX analyst price targets range from $640 to $800, a 21% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $747.5 consensus represents the middle ground. Our model's $448-$937 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into IDXX consensus models and risk factors.
View Analysis
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare